Pediatrix Medical Group’s first quarter results surpassed Wall Street’s revenue and profit expectations, yet the market responded negatively, reflecting inve...
Pediatrix Medical Group (NYSE:MD) reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported by higher pricing, improved collections and continued strength in payer mix despite modest volume declines across its service lines.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 3.9% year on...
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 3.9% year...
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting results this Tuesday before market hours. Here’s what you need to know. Ped...
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Pediatrix Medical Group has had an impressive run over the past six months as its shares have beaten the S&P 500 by 31.6%. The stock now trades at $23.07, ma...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services indust...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Pediatrix Medical Group’s fourth quarter was marked by a negative market reaction, driven by a combination of lower-than-expected non-GAAP earnings and year-on-year revenue declines. Management attributed the softer results primarily to a decrease in net patient volumes across all service lines, with Chief Financial Officer Kasandra H. Rossi citing "a tough comp" from the prior year as a key factor. Despite these volume pressures, Pediatrix was able to partially offset the impact through favorable payer mix, improved revenue cycle management collections, and higher patient acuity in neonatology, resulting in a notable increase in operating margin compared to the previous year.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $493.8 million. Its non-GAAP profit of $0.50 per share was 7.1% below analysts’ consensus estimates.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.7% year on year to $493.8 million. Its non-GAAP profit of $0.50 per share was 7.1% below analysts’ consensus estimates.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD)
will be announcing earnings results this Thursday before the bell. Here’s what to look for.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
